Companies › Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Neurology, Cardiovascular; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 18F-metaFluorobenzylguanidine (18F-mFBG) PET radiopharmaceutical for myocardial sympathetic innervation imaging | – | Phase 2 | Heart Failure; Parkinson Disease (PD); Cardiovascular Diseases | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04535193 | 18F-metaFluorobenzylguanidine (18F-mFBG) | Phase 1 | Cardiovascular Diseases | Cardiovascular | Mar 2025 |
| NCT06965621 | 18F-metaFluorobenzylguanidine (18F-mFBG) | Phase 2 | Heart Failure | Cardiovascular | Dec 2026 |
| NCT07176286 | 18F-metaFluorobenzylguanidine (18F-mFBG) | Phase 2 | Parkinson Disease (PD) | Neurology | Dec 2026 |
No annotated target.
–
Ever Neuro Pharma AMO Pharma Translational Sciences Edgewise Therapeutics CSPC Mingfule Pharmaceutical (Guangzhou)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.